ALEXANDRA PETROU: Open Payments
NPI 1114682234 · HOLMDEL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 31 payments from 11 companies in 2025. Trend: 2023 $109 · 2024 $334 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $96 |
| Novartis Pharmaceuticals Corporation | 4 | $86 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Genentech USA, Inc. | 3 | $51 |
| GENZYME CORPORATION | 2 | $37 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| BioCryst US Sales Co., LLC | 1 | $21 |
| LEO Pharma Inc. | 1 | $18 |
| Amgen Inc. | 1 | $17 |
Products named: NUCALA, DUPIXENT, XOLAIR, TEZSPIRE, Rhapsido, Sajazir, ORLADEYO, ADBRY.
Industry payments across NJ — which companies pay providers there.
